1972
Clinical trials with 5-[3,3-bis(2-chloroethyl)-1-triazeno]imidazole-4-carboxamide (NSC-82196) given intravenously.
Bagley C, Canellos G, Young R, Gallelli J, Devita V. Clinical trials with 5-[3,3-bis(2-chloroethyl)-1-triazeno]imidazole-4-carboxamide (NSC-82196) given intravenously. Cancer Chemotherapy Reports 1972, 56: 387-91. PMID: 19051499.Peer-Reviewed Original ResearchConceptsClinical trialsDose-limiting toxic effectPhase II trialBone marrow toxicityConsecutive daily injectionsTime of onsetDegree of severitySevere nauseaII trialObjective responseDaily injectionsMarrow toxicityPatientsTrialsToxic effectsToxicityNauseaVomitingPainLymphomaMelanomaTumorsLymphosarcomaAdministrationDose
1966
Preliminary clinical studies with ibenzmethyzin
DeVita V, Serpick A, Carbone P. Preliminary clinical studies with ibenzmethyzin. Clinical Pharmacology & Therapeutics 1966, 7: 542-546. PMID: 5939977, DOI: 10.1002/cpt196674542.Peer-Reviewed Original ResearchConceptsBone marrow depressionDaily oral dosesBone marrow toxicityPreliminary clinical studyMarrow depressionHodgkin's diseaseOral dosesWeekly injectionsMarrow toxicityAdverse reactionsMalignant melanomaOral administrationClinical studiesNeoplastic diseasePatientsAntitumor activityDiseaseNauseaVomitingSomnolenceNeurologicMelanomaAtaxiaAdministrationDose